Purchase of Tenecteplase

This tender concerns the procurement of Tenecteplase, a medication used to treat certain types of blood clots, such as those causing heart attacks or strokes. The procurement is based on actual need, indicating that the purchasing entity will order the medication as and when it is required, rather than in a single large batch. The contract duration extends until January 12, 2027. This approach allows for flexibility and ensures that the supply aligns with real-time demand, potentially minimizing waste and optimizing inventory management. The specific quantities and delivery schedules will be determined by the ongoing requirements of the procuring organization. Interested suppliers are expected to provide competitive offers for the supply of Tenecteplase, adhering to all relevant quality and regulatory standards for pharmaceutical products. Further details regarding technical specifications, delivery terms, and evaluation criteria will be provided in the full tender documentation. This procurement is crucial for ensuring the availability of essential medical supplies for patient care.

This is a supplies contract in the health and medical services and general supplies sectors, with a focus on Pharmaceuticals and Medical Equipment. Located in Estonia, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.